Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | SHBG | P04278 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28314696 | 0.98 | EPHX1 (0.33) | EPHX1KIF11SHBGKEAP1NFE2L2 | |
| SCHEMBL28315542 | 0.96 | EPHX1 (0.34) | EPHX1KIF11SHBGKEAP1NFE2L2 | |
| SCHEMBL21268844 | 0.96 | EPHX1 (0.34) | EPHX1KIF11SHBGKEAP1NFE2L2 | |
| SCHEMBL28315774 | 0.96 | EPHX1 (0.34) | EPHX1KIF11SHBGKEAP1NFE2L2 | |
| Magnesium SCHEMBL29456112 | 0.96 | EPHX1 (0.34) | EPHX1KIF11SHBGKEAP1NFE2L2 | |
| SCHEMBL28314663 | 0.96 | EPHX1 (0.34) | EPHX1KIF11SHBGKEAP1NFE2L2 | |
| SCHEMBL21269275 | 0.96 | EPHX1 (0.34) | EPHX1KIF11SHBGKEAP1NFE2L2 | |
| SCHEMBL9468355 | 0.81 | EPHX1 (0.38) | EPHX1KIF11SHBGKEAP1NFE2L2 | |
| SCHEMBL21269128 | 0.80 | EPHX1 (0.33) | EPHX1SHBGNAAA | |
| SCHEMBL21269077 | 0.80 | EPHX1 (0.33) | EPHX1SHBGNAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190256683-A1 | METAL SALTS OF MALONIC ACID AS NUCLEATING ADDITIVES FOR CRYSTALLINE THERMOPLASTICS | INDIAN OIL CORPORATION LIMITED (IN) | 2019-08-22 | — | — | US | claimed |
| EP-3527616-A1 | METAL SALTS OF MALONIC ACID AS NUCLEATING ADDITIVES FOR CRYSTALLINE THERMOPLASTICS | INDIAN OIL CORPORATION Ltd. (IN) | 2019-08-21 | — | — | EP | claimed |
| EP-3527616-B1 | METAL SALTS OF MALONIC ACID AS NUCLEATING ADDITIVES FOR CRYSTALLINE THERMOPLASTICS | INDIAN OIL CORP LTD (IN) | 2024-02-07 | — | — | EP | disclosed |
| US-11180630-B2 | Metal salts of malonic acid as nucleating additives for crystalline thermoplastics | INDIAN OIL CORPORATION LIMITED (IN) | 2021-11-23 | — | — | US | disclosed |
| US-20190256683-A1 | METAL SALTS OF MALONIC ACID AS NUCLEATING ADDITIVES FOR CRYSTALLINE THERMOPLASTICS | INDIAN OIL CORPORATION LIMITED (IN) | 2019-08-22 | — | — | US | disclosed |
| EP-3527616-A1 | METAL SALTS OF MALONIC ACID AS NUCLEATING ADDITIVES FOR CRYSTALLINE THERMOPLASTICS | INDIAN OIL CORPORATION Ltd. (IN) | 2019-08-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190256683-A1 | METAL SALTS OF MALONIC ACID AS NUCLEATING ADDITIVES FOR CRYSTALLINE THERMOPLASTICS | NUMA1, MNS1, ME1 | EPHX1 4463/4885KIF11 159/4885SHBG 4781/4885 |
| US-11180630-B2 | Metal salts of malonic acid as nucleating additives for crystalline thermoplastics | NUMA1, MNS1, ME1 | EPHX1 4463/4885KIF11 159/4885SHBG 4781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.